Saniona still the one to beat: Danish Biotech Weekly (28)

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, FluoGuide completed a 15 MSEK directed share issue, Zealand Pharma announced positive phase 1 results while Initiator Pharma finalized its buyback programme. Notably, Scandion Oncology rose nearly 50% without announcing any news.

Only 4 of the 20 listed, Danish biotech companies published news the past week. 7 of the 20 companies had a positive development in their share price for the week and 6 companies have had a positive share price performance year to date. Saniona continues to be the best performing stock this year with a price increase of more than 150%.

Company news the past week

Ascendis Pharma

No news the past week

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

No news the past week

Curasight

No news the past week

Evaxion Biotech

No news the past week

Expres2ion

No news the past week

Fluoguide

FluoGuide completes a directed share issue raising SEK 15 million (Link)

Genmab

No news the past week

Gubra

No news the past week

Initiator Pharma

Finalization of share buyback program in Initiator Pharma (Link)

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 (Link)

Y-mAbs Therapeutics

No news the past week

2cureX

Invitation to 2cureX Q2 update and Q&A session on July 12, 2023 at 20.00 (CET) (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS

On average, the Danish biotech stocks delivered a positive share price performance last week of 1.9%. The overall positive return was largely driven by Scandion Oncology that became the best performing stock with an 49% increase without announcing any company specific news. FluoGuide completed a directed share issue of 15 MSEK while Zealand Pharma announced positive phase 1 results for ZP8936 with potential against obesity and diabetes. Neither news had any significant effect on the share prices of the two companies. Curasight became the worst performing Danish biotech stock with a 9% decrease after a strong share price performance. The best stocks year-to-date include Curasight A/S, Fluoguide A/S, and Saniona AB after soaring 112-152%. Overall the Danish biotech stocks are in positive terrotory this year with a year-to-date return of 4.5%.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email